N-(Amino-PEG4)-N-Biotin-PEG4-acid

 CAS No.: 2100306-84-9  Cat No.: BP-501517 4.5  

N-(Amino-PEG4)-N-Biotin-PEG4-acid is a polyethylene glycol (PEG)-based PROTAC linker. N-(Amino-PEG4)-N-Biotin-PEG4-acid can be used in the synthesis of a series of PROTACs.

N-(Amino-PEG4)-N-Biotin-PEG4-acid

Structure of 2100306-84-9

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
PROTAC Linker
Molecular Formula
C₃₁H₅₈N₄O₁₂S
Molecular Weight
710.88

* For research and manufacturing use only. Not for human or clinical use.

SizePriceStockQuantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

  • mg to g scale for early stage;
  • CDMO and CMO support.
  • 24/7 customer service;
  • 100% quality assurance;
  • Efficient global delivery;
  • Over 95% customer satisfaction.
Popular Publications Citing BOC Sciences Products
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Shipping
Room temperature in continental US; may vary elsewhere.
IUPACName
3-[2-[2-[2-[2-[5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoyl-[2-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]ethyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]propanoic acid
InChI Key
AZKXAZTWSKMXDE-VWYPKUQYSA-N
InChI
InChI=1S/C31H58N4O12S/c32-6-10-41-14-18-45-22-24-47-20-16-43-12-8-35(7-11-42-15-19-46-23-21-44-17-13-40-9-5-29(37)38)28(36)4-2-1-3-27-30-26(25-48-27)33-31(39)34-30/h26-27,30H,1-25,32H2,(H,37,38)(H2,33,34,39)/t26-,27-,30-/m0/s1
Canonical SMILES
C1C2C(C(S1)CCCCC(=O)N(CCOCCOCCOCCOCCC(=O)O)CCOCCOCCOCCOCCN)NC(=O)N2
1. Development of N-F fluorinating agents and their fluorinations: Historical perspective
Teruo Umemoto, Yuhao Yang, Gerald B Hammond Beilstein J Org Chem. 2021 Jul 27;17:1752-1813.doi: 10.3762/bjoc.17.123.eCollection 2021.
This review deals with the historical development of all N-F fluorinating agents developed so far. The unique properties of fluorine make fluorinated organic compounds attractive in many research areas and therefore fluorinating agents are important. N-F agents have proven useful by virtue of their easy handling. This reagent class includes many types of N-F compounds: perfluoro-N-fluoropiperidine, N-fluoro-2-pyridone, N-fluoro-N-alkylarenesulfonamides, N-fluoropyridinium salts and derivatives, N-fluoroquinuclidium salts, N-fluoro-trifluoromethanesulfonimide, N-fluoro-sultams, N-fluoro-benzothiazole dioxides, N-fluoro-lactams, N-fluoro-o-benzenedisulfonimide, N-fluoro-benzenesulfonimide, 1-alkyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane salts, N-fluoropyridinium-2-sulfonate derivatives, 1-fluoro-4-hydroxy-1,4-diazoniabicyclo[2.2.2]octane salts, N-fluorodinitroimidazole, N-fluoro-trichloro-1,3,5-triazinium salt, N-F ethano-Tröger's base derivatives, N-fluoro-methanesulfonimide, N-fluoro-N-arylarenesulfonamides, bisN-F salts such as N,N'-difluorobipyridinium salts and N,N'-difluoro-1,4-diazoniabicyclo[2.2.2]octane salts, and their many derivatives and analogs, including chiral N-F reagents such as optically active N-fluoro-sultam derivatives, N-fluoro-alkaloid derivatives, DABCO-based N-F derivatives, and N-F binaphthyldisulfonimides. The synthesis and reactions of these reagents are described chronologically and the review also discusses the relative fluorination power of each reagent and their mechanisms chronicling developments from a historical perspective.
2. Crystal structures of three N,N,N'-tris-ubstituted thio-ureas for reactivity-controlled nanocrystal synthesis
Evert Dhaene, Isabel Van Driessche, Klaartje De Buysser, Kristof Van Hecke Acta Crystallogr E Crystallogr Commun. 2022 Jan 14;78(Pt 2):184-190.doi: 10.1107/S2056989022000147.eCollection 2022 Jan 1.
The synthesis and single-crystal X-ray structures of three N,N,N'-tris-ubstituted thio-ureas are reported, namely N,N,N'-tri-benzyl-thio-urea, C22H22N2S (1), N-methyl-N,N'-di-phenyl-thio-urea, C14H14N2S (2), and N,N-di-n-butyl-N'-phenylthio-urea, C15H24N2S (3). The influence of the different substituents on the thio-ureas is clear from the delocalization of the thio-urea C-N and C=S bonds, while the crystal structures show infinite chains of N,N,N'-tri-benzyl-thio-urea (1), hydrogen-bonded pairs of N-methyl-N,N'-di-phenyl-thio-urea (2) and hexa-mer ring assemblies of N,N-di-n-butyl-N'-phenylthio-urea (3) mol-ecules. The above-mentioned compounds were synthesized via a mild, general procedure, readily accessible precursors and with a high yield, providing straightforward access to a whole library of thio-ureas.
3. Histoplasmosis in Children; HIV/AIDS Not a Major Driver
Bassey E Ekeng, Kevin Edem, Ikechukwu Amamilo, Zachary Panos, David Denning, Rita O Oladele J Fungi (Basel). 2021 Jun 30;7(7):530.doi: 10.3390/jof7070530.
The classification of histoplasmosis as an AIDS-defining illness has largely attributed its occurrence in people to the presence of HIV/AIDS especially in Africa. Prior to the advent of the HIV/AIDS epidemic, several cases of histoplasmosis were documented both in the pediatric and adult populations. Our review revealed 1461 reported cases of pediatric histoplasmosis globally in the last eight decades (1939-2021). North America (n = 1231) had the highest number of cases, followed by South America (n = 135), Africa (n = 65), Asia (n = 26) and Europe (n = 4). Histoplasmosis was much more common in the non-HIV pediatric population (n = 1418, 97.1%) compared to the HIV population. The non-HIV factors implicated were, childhood malignancies (n = 207), such as leukemias and lymphomas as well as their treatment, lung diseases (n = 7), environmental exposures and toxins (n = 224), autoimmune diseases (n = 12), organ transplants (n = 12), long-term steroid therapy (n = 3), the use of immunosuppressive drugs such as TNF-alpha inhibitors (n = 7) malnutrition (n = 12), histiocytosis (n = 3), Hyper immunoglobulin M and E syndromes (n = 15, 1.2%), pancytopenia (n = 26), diabetes mellitus (n = 1) and T-cell deficiency (n = 21). Paediatricians should always consider or rule out a diagnosis of histoplasmosis in children presenting with symptoms suggestive of the above clinical conditions.

Stock concentration: *
Desired final volume: *
Desired concentration: *

L

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2

* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O c22h30n40
g/mol
g

Related Product Recommendations

BOC Sciences Support

Please contact us with any specific requirements and we will get back to you as soon as possible.


  • Verification code

We invite you to contact us at or through our contact form above for more information about our services and products.

USA
  • International:
  • US & Canada (Toll free):
  • Email:
  • Fax:
UK
Germany
Inquiry Basket